Impact of ketorolac on opioid consumption after open heart surgery by Neubauer, Laura et al.
Baptist Health South Florida 
Scholarly Commons @ Baptist Health South Florida 
All Publications 
12-9-2020 
Impact of ketorolac on opioid consumption after open heart 
surgery 
Laura Neubauer 
Baptist Hospital of Miami, LauraNeu@baptisthealth.net 
Radhan Gopalani 
Baptist Hospital of Miami, radhang@baptisthealth.net 
Kristen de Almeida 
Baptist Hospital of Miami, KristenDe@baptisthealth.net 
Andrea Marr-Peralto 
Baptist Hospital of Miami; Miami Cardiac & Vascular Institute, AndreaMPe@baptisthealth.net 
Follow this and additional works at: https://scholarlycommons.baptisthealth.net/se-all-publications 
 Part of the Heterocyclic Compounds Commons, and the Pharmacy and Pharmaceutical Sciences 
Commons 
Citation 
Neubauer, Laura; Gopalani, Radhan; de Almeida, Kristen; and Marr-Peralto, Andrea, "Impact of ketorolac on 
opioid consumption after open heart surgery" (2020). All Publications. 3761. 
https://scholarlycommons.baptisthealth.net/se-all-publications/3761 
This Conference Poster -- Open Access is brought to you for free and open access by Scholarly Commons @ 
Baptist Health South Florida. It has been accepted for inclusion in All Publications by an authorized administrator 
of Scholarly Commons @ Baptist Health South Florida. For more information, please contact 
Carrief@baptisthealth.net. 
RESULTS
RESULTS
Impact of ketorolac on opioid consumption after open heart surgery
Laura Neubauer, Pharm.D.; Radhan B. Gopalani, Pharm.D., BCPS, BCCP; Kristen E. De Almeida, Pharm.D., BCCP; 
Andrea Marr-Peralto, DNP, AGACNP, APRN 
• Opioids are the most common analgesics used in the 
postoperative period despite their potentially serious side 
effects1,2
• The use of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) 
after open heart surgery for adjunctive pain control is 
controversial given the potential risks of acute kidney 
injury (AKI) with these agents
• Despite the FDA contraindication for use in patients 
immediately following coronary artery bypass graft (CABG) 
surgery, NSAIDs are commonly used in this setting with 
one study showing ketorolac being the agent prescribed in 
90% of cases1
• According to the current Baptist Health post open heart 
order set, ketorolac use is not recommended in patients 
with active bleeding, Scr >1.6 mg/dL, > 80yo, or recent 
history of GI bleed
To evaluate the use of ketorolac in the immediate 48 hours
after cardiac surgery at Baptist Hospital of Miami and South
Miami Hospital
Study Design: Multicenter, retrospective quality 
improvement project
Inclusion Criteria:
‒ Adults ≥ 18 years of age 
‒ Underwent open heart surgery (CABG, valvular 
replacement, CABG/valvular surgery, aortic surgery) 
performed between 1/1/2020 and 3/31/2020
Exclusion Criteria:
‒ Pregnant at time of hospitalization 
Primary Outcome:
‒ Opioid consumption in morphine milligram equivalents 
(MME) within 48 hours after open heart surgery
Secondary Outcomes:
‒ Incidence of AKI within 48 hours after open heart 
surgery (↑ in Scr > 0.3 mg/dL in 48 hours)
‒ Opioid-induced adverse drug reactions (ADRs)  
Controlling for Confounding Factors
‒ To control for selection bias, patients with baseline CKD 
and those who received fentanyl (IV push or infusion) 
during the immediate 48 hours postoperatively were 
removed from the final analysis 
All authors of this presentation have nothing to disclose concerning possible
financial or personal relationships with commercial entities that may have
direct or indirect interest in the subject matter of this presentation.
• Use of ketorolac in the immediate postoperative period did 
not impact opioid consumption
• Risk of postoperative AKI did not increase with ketorolac 
o Observed statistically significant difference in AKI is not 
clinically meaningful and is likely due to the patient 
population under review
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• Baseline demographics were not statistically different 
between cohorts except for age (p<0.05)
• There was no statistical difference in opioid consumption 
between cohorts (p=0.11)
• Morphine and oxycodone/acetaminophen were the most 
commonly received opioids. Acetaminophen IV was the most 
commonly received non-opioid analgesic
• Patients who did not receive ketorolac had a significantly 
higher rate of postoperative AKI (p<0.05), possibly due to the 
significantly older population in this cohort; other risk factors 
for AKI were similar between cohorts
• Use of ketorolac per the recommendations in the Baptist 
Health open heart order set may have additionally 
contributed to selection bias 
• A total of 3 opioid-induced ADRs resulting in treatment 
discontinuation were reported (hallucinations, slight over-
sedation, and nausea/vomiting)
• Retrospective
• Small study duration and sample size 
• Selection bias
• Pain scores could not be evaluated due to inconsistent 
documentation
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Demographics
Ketorolac
(n=22)
No Ketorolac 
(n=45)
P-value 
Avg. age, years (SD) 63.2 + 9.2 68.4 + 9.0 < 0.05
Age > 75 years – n (%) 2 (9) 11 (24.4) 0.20
Gender – male, n (%) 18 (81.8) 33 (73.3) 0.55
Outpatient use of opioids – n (%) 1 (4.5) 1 (2.2) 0.55
Outpatient use of adjuvant pain meds – n (%) 2 (9) 4 (8.9) 1.00
Non-Elective Procedure – n (%) 16 (73) 28 (62) 0.40
Avg. Scr on admission, mg/dL (SD) 0.99 + 0.23 1.04 + 0.32 0.50
Avg. Scr day of surgery, mg/dL (SD) 0.90 + 0.16 0.98 + 0.28 0.21
Avg. Scr 48h postop, mg/dL (SD) 0.92 + 0.19 1.18 + 0.53 < 0.05
OTHER RISK FACTORS FOR AKI
Use of CPB – n (%) 20 (90.9) 39 (86.7) 0.62
Dehydration postop (BUN:Scr > 20:1) – n (%) 12 (54.5) 28 (62.2) 0.55
Use of vasopressors postop – n (%) 19 (86.4) 32 (71.1) 0.17
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Analgesic – n (%)
Ketorolac
(n=22)
No Ketorolac 
(n=45)
Morphine 22 (100) 41 (91.1)
Acetaminophen IV 21 (95.5) 41 (91.1)
Oxycodone/Acetaminophen 19 (86.4) 37 (82.2)
Acetaminophen PO 5 (22.7) 15 (33.3)
Hydromorphone 0 4 (8.9)
Gabapentin 0 3 (6.7)
Tramadol 1 (4.5) 1 (2.2)
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